At the BIO International Convention 2026 in San Diego, Theertha introduced PepXen™ to the global peptide and insulin manufacturing community — a high-expression platform engineered to deliver more product in less volume, with better economics.
The response was outstanding — genuine conversations at the booth, from process engineers to business leaders exploring what a smaller process footprint means for their next facility.
47%
lower process volume
14%
higher product recovery
25%
higher protein loading
45%
smaller footprint
“More product, less volume, better economics” — enabling higher output, lower cost and faster scale-up for insulin, GLP-1 and recombinant peptides.
Want to see how PepXen™ applies to your molecule? Talk to our team.